Cancer is the second leading cause of death in the United States and there is a continuing need to provide new, safer cancer drugs to patients. We at NexusPharma are actively pursuing this unmet need to provide effective discovery tools to select novel therapeutics with fewer side effects for cancer patients. Together with Fox Chase Cancer Center, a co-founder of the company, we are dedicated to the development of patient derived tumor disease models to advance the discovery of effective drugs.
What began in the research and clinical laboratories of Fox Chase Cancer Center to support better treatment of patients, has resulted in the a panel of patient derived xenograft (PDX) models to validate the biological activity of compounds in cancer treatment.
These technologies have become the cornerstone for the company to create a pipeline of novel PDX models as more predictive drug discovery tools. NexusPharma is also characterizing its PDX models by genomic analysis such as for example mRNA sequencing to unravel critical cancer signaling networks. In addition, sequencing genetic profiles are validated using orthogonal quantitative methods.
NexusPharma is developing a database of compounds and their activities in various PDX or PDX derived cell lines. Together with informations about the genetics of tumor models, we are building a predictive correlation between biological targets and compound efficacy.View Services
NexusPharma is a member of Genesis Drug Discovery and Development (GD3) the contract research organization (CRO) of Genesis Biotechnology Group® (GBG). GD3 is a preclinical Contract Research Organization which offers an integrated portfolio of drug discovery services from target validation and assay development to advancing compounds from “hit to lead” to “lead optimization”. GD3’s members include: